gout
Conditions
Interventions
control group:Benzbromarone Tablet 25mg qd +Sodium Bicarbonate Tablets 1g tid (Initial treatment)
Benzbromarone Tablet 50mg qd +Sodium Bicarbonate Tablets 1g tid (Adjustment based on uric acid level)
experimental group:Benzbromarone Tablet 25mg qd +qinglingweishi 3.5g bid (Initial treatment)
Benzbromarone Tablet 50mg qd + qinglingweishi 3.5g bid (Adjustment based on uric acid level)
Sponsors
Affiliated Hospital of Qiingdao University
Eligibility
Sex/Gender
Male
Age
17 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) 18~70 years old male; 2) conform to the diagnostic criteria of primary gout, 8.0 mg/dL (476 micromol/L) < serum uric acid < 9.7 mg/dL (576 umol/L); 3) morning urine pH was less than 6; 4) no acute gouty arthritis authors were found in the first 2 weeks and 2 weeks of elution; 5) voluntarily attend and sign informed consent.
Exclusion criteria
Exclusion criteria: 1) allergic to all drugs, foods or their ingredients, or allergic to symptoms or allergic constitution; 2) In patients with active liver disease or cirrhosis, or with abnormal liver function, serum alanine aminotransferase (ALT) and glutamic oxaloacetic aminotransferase (AST) exceeded the upper limit of normal range by 1.5 times; 3) patients with active gastrointestinal ulcer; 4) thyroid dysfunction; 5) glomerular filtration rate was <60ml/min; 6) Severe heart disease patients, such as: decompensated heart failure (NYHA stage III and IV); unstable angina pectoris; past 12 months with a history of myocardial infarction; 7) kidney stones, renal cysts, sponge kidney or other obstructive nephropathy; 8) patients with xanthine inuresis; 9) rheumatoid arthritis and other causes of joint disease requiring treatment; 10) azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, bizinamide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (more than 325mg/day) or other salicylic acid substances, losartan, intravenous colchicine treatment; 11) patients with secondary hyperuricemia caused by hematological diseases, renal diseases or tumor radiotherapy and chemotherapy; 12) brain disease, abnormal judgement; mental illness can not cooperate; 13) alcoholics or drug addicts; 14) Pregnancy, breastfeeding or intentional pregnancy, women of childbearing age who do not use effective contraceptive measures (referring to intrauterine devices, oral contraceptives and obstructive measures); 15) during the first three months of the study, other clinical trials were included; 16) malignant tumor and active tuberculosis; 17) concurrent with other diseases, and the researchers believe that the effect of evaluation or compliance is poor; 18) those taking corticosteroids; 19) white blood cell count < 4 x 10^9/L, or platelets < 100 x 109/L, or hemoglobin 90g/L; 20) for any other reason, the researchers consider it inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood uric acid value;PH of urine; | — |
Secondary
| Measure | Time frame |
|---|---|
| fraction excretion of uric acid;Triglyceride;AST ALT;blood pressure;cholesterol;blood sugar;Urinary system ultrasound;eGFR, Estimated Glomerular Filtration Rate; | — |
Countries
China
Contacts
Public ContactLi Changgui
Affiliated Hospital of Qiingdao University
Outcome results
None listed